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Abstract
Patients with Parkinson’s disease (PD) sometimes develop impulsive compulsive behaviours (ICBs) due to their
dopaminergic medication. We compared 26 impulsive and 27 non-impulsive patients with PD, both on and off medication,
on a task that examined emotion bias in decision making. No group differences were detected, but patients on medication
were less biased by emotions than patients off medication and the strongest effects were seen in patients with ICBs. PD
patients with ICBs on medication also showed more learning from negative feedback and less from positive feedback,
whereas off medication they showed the opposite effect.
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Introduction
The basal ganglia, the prefrontal cortex, the amygdala and the
fusiform gyrus are all believed to be involved in face processing
[1,2,3,4]. Therefore, pathology in these circuits could lead to deficits
in face processing. Deficits in recognizing facial expressions,
particularly those expressing anger and fear, have been demon-
strated in patients with various kinds of addictions and compulsive
behaviours [5,6]. Results in patients with Parkinson’s disease (PD)
on the other hand are still inconclusive with some [7,8,9,10,11] but
not all [12] studies showing impairment of facial processing.
In this study we tested PD patients on and off their usual
dopaminergic medication to examine the effects of impulsivity and
dopamine in decision making in a task relying on emotional cues.
Participants were asked to learn by trial and error, which of two
faces (a happy and an angry face) was associated with a small
monetary reward and then to pick that face as often as possible. In
theory the facial expression should not influence decision making,
however studies in healthy volunteers showed that subjects would
select the happy face more often than the angry one, especially
when learning was difficult [13]. This behaviour is called ‘positive
emotional bias’. In contrast negative biases in processing
emotional information have been found in patients with
depression [14]. Both positive and negative emotional biases can
lead to irrational decision making which might lead to damaging
behaviours, such as overconfidence or depression. From a different
perspective, however, the emotion bias may reflect appropriate
processing of social communication information, which is
important for social function.
A functional imaging study has shown that emotion bias
correlates with activation in the anterior cingulate, which is known
to have the greatest dopamine innervation in the cortex [15] and
the temporo-parietal junction [16]. Thus dopamine and especially
unphysiological dopaminergic medication might alter emotion
bias. In contrast to the emotion bias, reward feedback information
in this task activated the ventral striatum and ventral-medial
prefrontal cortex, which was necessary to learn which face was
most often being rewarded [16].
Impulsive compulsive behaviours (ICBs) such as pathological
gambling and compulsive sexual behaviour are triggered by
dopaminergic medication. Although some risk factors for ICBs
and behavioural changes on metric tasks have been described [17]
it is unclear whether dopamine induced changes in emotional bias
are a potential risk factor for impulsivity. ICBs predominate in the
‘‘on’’ state which might suggest that dopaminergic medication
changes the value of social feedback, and might reduce emotional
bias.
Thus we speculated that PD patients with ICBs (PD+ICB)
would be less biased by emotions in their ‘‘on’’ versus ‘‘off’’ state
and hypothesised that controls would learn better on this task than
PD+ICB patients.
Methods
Objectives
To assess the effects of dopaminergic medication on sensitivity
to social bias in PD patients with and without ICBs.
Participants
Twenty five PD patients without ICBs (PD2ICB) and 26
PD+ICB patients were recruited from the National Hospital for
Neurology and Neurosurgery, Queen Square, London. All
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patients fulfilled the Queen Square Brain Bank criteria for the
diagnosis of PD [18] and were taking L-dopa. PD+ICB patients
were diagnosed using proposed criteria [19,20,21,22]. Many
PD+ICB patients had more than one ICB (see Table 1). L-dopa
equivalent units (LEU) of patients’ regular daily dopamine
replacement therapies were calculated as described elsewhere
[22]. All patients showed a significant improvement (.30%
improvement) after dopamine replacement therapy intake on the
UPDRS (part 3) motor score. Sixteen healthy elderly volunteers
matched for age, gender and education were recruited, usually
from amongst the patient’s spouses or partners. Patients who
scored under 26/30 points on the Mini Mental State Examination
(MMSE) [23] were excluded from this study.
Description of Procedures
PD patients were tested before and after their usual anti-
Parkinson medication in a counterbalanced sequence to account
for order effects. All patients who were tested in their ‘‘off
medication state’’ did not take their usual anti-Parkinson
medication, including both L-dopa and any dopamine agonists,
for at least 12 hours and performed the task between 8.00am and
9.00am. They were then retested in their ‘‘on medication’’ state
the following day, usually mid mornings. Those patients who were
tested ‘‘on medication’’ first performed this task usually in mid-
morning when their motor symptoms were well controlled. They
were re-visited on the following day prior to their medication for
the second test. Results were compared with 16 controls who were
matched for age to the PD+ICB group and who were tested over
two days but did not take any anti-Parkinson medication. At the
end of the study all participants received a modest honorarium
depending on their final score (usually £5–£10).
Face decision task
We used a probabilistic face decision task, which has been
described previously [13]. Participants performed the task on a
laptop computer either at home or in a quiet room to minimize
distractions. They were told to choose between 2 stimuli (a happy
and an angry face) which were presented side by side on a black
screen and had different probabilities of being rewarded (Figure 1).
Feedback was given immediately and correct choices were
rewarded with 10 pence whereas incorrect choices resulted in no
reward. In total participants performed 4 blocks consisting of 26
trials per block and were told to maximize their winnings by
picking the rewarded picture as many times as possible. The
reward probabilities across the 4 blocks were kept constant (60:40)
and were mapped to each emotion in a balanced manner, such
that the happy face was the high probability stimulus in 2 blocks
and the angry face in 2 blocks. Two identities were also used in
interleaved blocks. Feedback was given stochastically, i.e. after
each selection, rewards were delivered pseudo-randomly with a
fixed probability that depended on the face and the block [13].
Emotion bias was determined by comparing how often, when
participants do not select the most often rewarded face, they select
the happy face as opposed to how often they select the angry face.
Heuristically, one can also ask, given equivalent reward feedback
for both faces, how often are participants selecting the happy face?
If it’s well over 50% of the time, then they are biased towards the
happy face.
Ethics
All participants provided written informed consent according to
the declaration of Helsinki and the study was approved by the
UCLH Trust ethics committee.
Statistical methods
All data analysis was carried out in Matlab. Details about the
statistical analysis have been reported elsewhere [13,24]. Briefly,
we fit a statistical model known as an ideal observer, which tracked
positive and negative feedback given for each face, and made an
optimal decision about which face should be chosen for each trial.
The model made its decision based on only the reward feedback,
so it was not biased by the emotional content of the face. The
Table 1. Demographic characteristics.
Controls (1) PD+ICB (2) PD2ICB (3)
t value, x2 and
F-value p-value; columns
Participants(no.) 16 26 27
Age (yrs) 59.1611.8 58.069.3 65.365.3 F = 5.2 0.008*;(1,2,3)
Gender (male) 14 22 24 x2 = 5.9 0.3; (1,2,3)
At PD onset (yrs) 47.769.5 55.367.4 t = 3.28 0.002*;(2,3)
PD Disease duration (yrs) 11.064.2 10.066.6 t = 0.52 0.48;(2,3)
Education (yrs) 13.163.2 13.162.8 14.762.5 F = 2.4 .0.09; (1,2,3)
LEU dose(mg/day) 934.26407 740.16369 t = 1.8 0.072;(2,3)
PD patients currently using DA 13/26 21/27 x2 = 5.1 0.024*;(2,3)
UPDRS on 16.2610.6 21.169.0 t = 1.7 0.09;(2,3)
UPDRS off 31.0611.3 32.1610.6 t = 0.5 0.6;(2,3)
Improvement in UPRDS (%) 47.7 34.2
Hypersexuality 12
PG 13
Punding 7
Shopping 5
UPDRS =Unified Parkinson’s Disease Rating Scale; LEU= L-dopa equivalent units; DA= dopamine agonists. All values are mean 6 SD. Significant differences are labelled
with ‘‘*’’. P-values refer to columns indicated in brackets. Controls (column 1), PD+ICB (column 2), PD2ICB (column 3).
doi:10.1371/journal.pone.0032889.t001
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choices of the participants could then be compared to the optimal
choices of the model, which were based only on reward feedback.
Analysis of variance was carried out on emotion bias, overall
learning, and the effects of positive vs. negative feedback. In all
cases, these parameters were computed for each subject, and then
an ANOVA was run with the corresponding behavioural measure
as a dependent variable. Emotion bias and overall learning were
characterized by compiling a 262 contingency table for each
subject. Each cell in the contingency table contained counts of
choice patterns of the model and the observer. Based on the counts
in the table, emotion bias was computed as:
bias~p subject~happy model~angryjð Þ{
p subject~angry model~happyjð Þ:
ð1Þ
Reward learning was correspondingly given by:
learning~p subject~happy, model~happyð Þz
p subject~angry, model~angryð Þ:
ð2Þ
Results
Demographic and clinical features
Across groups there was a significant effect of age (F(2,66) = 5.3,
p = 0.008). Post hoc analysis showed that the PD2ICB group was
older than the PD+ICB group (p= 0.009). There was no difference
between controls and PD or PD+ICB patients (p.0.08). PD+ICB
patients had a significantly younger disease onset relative to
PD2ICB patients (t52 = 3.28, p = 0.002). There was no difference
in LEU dose, disease duration or years of education between both
patient groups. Further there was no group difference in UPDRS
part 3 motor scores prior to (‘off-state’) and similarly no group
difference after medication (‘on-state’). Significantly more
PD2ICB than PD+ICB patients were treated with a dopamine
agonist, which is in line with accepted clinical guidelines of
managing an ICB in PD (see table 1).
Face decision task
We first examined the PD2ICB and PD+ICB groups on and off
medication, excluding controls, with respect to emotion bias
(Fig. 2A,B) and overall reward learning (Fig. 2B,C). Emotion bias
is defined as choosing the happy face when they should choose the
angry face vs. choosing the angry face when they should choose
the happy face. Complementing this, reward learning is defined as
the proportion of times that participants chose the angry face
when they should have chosen the angry face (where ‘‘should’’ is
estimated using the ideal observer model) and the number of times
participants chose the happy face when they should have chosen
the happy face (see methods). Thus, these two measures assess
complementary aspects of the decision process.
We first examined just the PD groups off and on medication.
We found that dopamine medication decreased the emotion bias
across groups (F1, 48 = 6.29, p= 0.016), thus all patients chose the
angry picture more often in their ‘on’ compared to their ‘off’ state.
There was no difference between groups in emotion bias
(F1, 48 = 2.57, p = 0.115) and no interaction between medication
and group (F1, 48 = 0.24, p = 0.627). Further, there was no effect of
fraction correct performance (reward learning), when included as a
covariate, on emotion bias (F1, 48 = 0.16, p= 0.689). Thus,
participants who had a larger emotion bias did not necessarily
learn less. When the PD groups were analysed individually to
examine medication effects, there was a significant decrease in
emotion bias in the PD group on vs. off medication (F1, 24 = 4.56,
p = 0.043) but not in the ICB group (F1, 25 = 2.48, p = 0.128). In
contrast to the emotion bias, there were no effects of medication
(F1, 49 = 1.65, p = 0.205) or group (F1, 49 = 1.31, p = 0.257) on
overall learning (Fig. 2C).
We next compared the PD2ICB and PD+ICB groups, off and
on medication, to controls, pair-wise. However, there were no
significant group differences in emotion bias (p.0.071). Following
this, we carried out planned comparisons on emotion bias
separately in each group, to see if each group was significantly
affected by the facial expression (Fig. 2B). A significant positive
emotion bias indicates that a group is significantly biased by the
emotion expression, choosing happy more than angry, given
equivalent reward feedback. There were significant effects of
emotion bias in the PD2ICB group on medication (t24 = 3.09,
p = 0.005), off medication (t24 = 5.37, p,0.001) and ICB group off
medication (t25 = 2.98, p = 0.006) and controls (t15 = 3.36,
p = 0.005). The PD+ICB on medication group just missed
significance (t25 = 2.05, p= 0.051). For overall learning perfor-
mance, the PD2ICB on (t24 = 4.11, p,0.001) and control
(t15 = 2.17, p = 0.048) groups were above chance, but all other
groups were at chance (p.0.156).Thus, all patients, except the
Figure 1. Face task. A: One happy and one angry face were presented side by side on a black screen. B: After a choice (in this case angry face) visual
and acoustic feedback was given immediately.
doi:10.1371/journal.pone.0032889.g001
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PD+ICB on group, chose the happy face significantly more often
than the angry face, given equivalent reward feedback.
In the final analysis we split overall learning into parameters
which separately measured learning from positive and negative
feedback in the PD groups off and on medication (Fig. 3). Results
from this analysis have to be interpreted with caution, as the
groups generally did not show robust learning, measured as
choices which were consistent with the ideal observer, except the
PD2ICB patients on medication. It is still possible, however, that
the participants were responding to positive and negative
feedback, without integrating it effectively over trials. We found
that in the PD group there were no effects of medication on
learning from positive vs. negative feedback (F1, 24 = 0.23,
p = 0.629) or medication by feedback type interactions (F1,
24 = 0.1, p = 0.753). However, in the PD+ICB group we found
that there was a significant medication by feedback type
interaction (F1, 25 = 7.35, p= 0.008) but no main effect of
medication (F1, 25 = 0.57, p= 0.452). Thus, consistent with our
previous study [25], increased dopamine levels in the PD+ICB
group increased sensitivity to negative feedback and decreased
sensitivity to positive feedback.
Discussion
All patients chose the happy face more than the angry face,
when expressions were matched for reward history, in their ‘off’
versus ‘on’ state. Furthermore, when examined pair-wise there
were no differences in emotion bias or learning between the
patient groups and the control group. This might be because
participants generally were not able to learn and integrate the
reward information effectively, since their behaviour did not
correlate well with the ideal observer, which is a purely statistical
model of how one should learn. When each group was analysed
individually, we found that all groups, other than the PD+ICB
group ‘on medication’, had a significant emotion bias and
preferred the happy to the angry face. Our finding is consistent
with previous studies using the same task [16,24,26]. Thus,
dopaminergic medication in PD appears to decrease sensitivity to
social bias in decision making. This reduction of emotional bias
‘on medication’ is particularly interesting since it has been
reported that the processing of negative emotions is impaired in
PD [27] and improves after dopaminergic medication [9,28]. In
our study however PD patients in general and particularly
PD+ICB patients picked the angry picture more often in their
‘on’, rather than ‘off’ state. The lack of emotional bias in PD+ICB
patients suggests that these patients might be prepared to ignore
negative feedback in the form of an angry face more easily when
associated with a potential short term reward. It is also possible
that this shift away from emotional biases could mean that
PD+ICB patients care less about other’s emotions, reflecting
reduced empathy in the patients. Several of the PD+ICB patients
spontaneously reported during testing that they ‘anticipated’ the
correct choice. This anticipation may be mediated via the ventral
striatum and anticipation of a conflict is processed via the anterior
cingulate [29,30]. This type of response has also been found in
another task in which participants could control the amount of
evidence they gathered before making a decision [31].
Thus, PD+ICB patients may learn poorly in some conditions
because they might use irrational estimates of correct responses,
rather than trying to learn from previous trials.
We found that both patient groups selected angry faces less than
controls, although none of the groups differed significantly from
controls. Patients with schizophrenia also select angry faces less
often than controls, given equivalent reward evidence [26]. In our
study, increasing dopamine levels decreased this emotional bias in
both PD groups. This would be consistent with the hypothesis that
effects seen in the study of patients with schizophrenia were driven
more by their medication status than by a possible increase in
striatal dopamine levels [32,33].
The nonapeptide oxytocin can decrease emotion bias in this
task, specifically by increasing choices of angry faces when the
evidence supports angry faces [24]. Interestingly, the results in the
present study tended to be consistent across levels of evidence for
each face. One could have hypothesized that dopamine modula-
tion may have affected learning from reward feedback which has
been found in some [34,35] but not all studies in PD [36], without
affecting social processing [24]. We found effects of dopamine on
learning in this study, consistent with our previous results [25].
Work in rodents has shown consistently that dopamine and
oxytocin can interact [37] and in humans oxytocin can increase
generosity, possibly by inducing striatal dopamine release [38]
suggesting that dopamine and oxytocin may interact to determine
Figure 2. Behavioral results. All error bars are 1 s.e.m. A. Emotion bias for each group. B. Evidence vs. choice curve showing increased selection of
happy faces when evidence supports angry face. C. Percent correct for each group.
doi:10.1371/journal.pone.0032889.g002
Figure 3. Learning from positive vs. negative feedback. Error
bars show 1 s.e.m. A. Parameter values from the Bayesian model in
PD+ICBs. B. Parameter values in PDs.
doi:10.1371/journal.pone.0032889.g003
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the effects of social stimuli on behaviour. Of note dopamine
increases altruistic punishment only in PD+ICB patients but not in
non-impulsive PD patients [39]. Similarly oxytocin can increase
punishment behaviour towards competing groups [40].
In an fMRI study of this task, larger modulation of blood-
oxygen-level dependent (BOLD) responses by reward prediction
error in the anterior cingulate and temporal parietal junction,
were correlated with smaller emotion bias effects. Further those
subjects that learned best in this task had the smallest modulation
of BOLD responses by reward prediction error [16]. Thus,
learning and increased BOLD modulation by reward prediction
error appear to be inversely correlated. Therefore the decreased
social bias seen in this study may be driven by increased reward
prediction error processing in the anterior cingulate and/or the
temporo-parietal junction. In previous work on the Stroop task,
which is likely mediated by the anterior cingulate as well [41], we
have found that PD2ICB and PD+ICB patients performed
similarly at a group level, but medication improved performance
in both groups, as well as improving cognitive flexibility [42]. This
is consistent with the hypothesis that dopamine in the anterior
cingulate is mediating the effects we have found in this study.
In summary, dopaminergic medication decreased sensitivity to
social bias in both groups of PD patients, in the absence of group
effects and none of the groups differed from matched controls.
Our results might imply that PD+ICB patients ‘on medication’ are
less affected by emotional feedback, which could be partly
responsible for their difficulties integrating into society and
following social norms. This is of interest in relation to the finding
of increased schizotypy in PD with ICBs [43]. We also found
effects of dopamine on the balance between learning from positive
vs. negative feedback in the PD+ICB group, but not in the
PD2ICB group.
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